Hae

RHCO ANNOUNCES COOPERATION WITH WORLDLINE

Retrieved on: 
Wednesday, October 20, 2021

The strategic partnership would bring OkePay and Readies, the comprehensive back-end Payment Platform and the Prepaid e-Voucher operated by RHCO, to all the merchants that have a connection with Worldline.

Key Points: 
  • The strategic partnership would bring OkePay and Readies, the comprehensive back-end Payment Platform and the Prepaid e-Voucher operated by RHCO, to all the merchants that have a connection with Worldline.
  • Worldline is the European leader in the payments and transactional services industry and #4 player worldwide.
  • www.worldline.com
    The collaboration will let all merchants connecting with Worldline have the option to pay by OkePay or Readies.
  • Richard Klitsie, CEO of RHCO stated, Worldline is a worldwide leader in the payments and transactional services industry, and we are excited to work with Worldline.

Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks

Retrieved on: 
Thursday, August 5, 2021

The validated Angioedema Quality of Life Questionnaire (AE-QoL) was among the patient-reported outcome tools used to evaluate patients quality of life (QoL).

Key Points: 
  • The validated Angioedema Quality of Life Questionnaire (AE-QoL) was among the patient-reported outcome tools used to evaluate patients quality of life (QoL).
  • The HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE) is an evaluation of the long-term efficacy and safety of TAKHZYRO in hereditary angioedema (HAE) patients of at least 12 years of age and older.
  • Rollover patients received a dose of 300 mg TAKHZYRO on Day 0 and then every two weeks after their first attack.
  • The patient or caregiver should be trained by a healthcare professional.7
    Please consult the TAKHZYRO Summary Product Characteristics (SmPC) before prescribing.

BioCryst Reports Second Quarter 2021 Financial Results and Upcoming Key Milestones

Retrieved on: 
Thursday, August 5, 2021

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2021, and provided a corporate update.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced financial results for the second quarter ended June 30, 2021, and provided a corporate update.
  • On July 10, 2021, the company announced data presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2021.
  • Selling, general and administrative expenses for the second quarter of 2021 increased to $26.3 million, compared to $13.9million in the second quarter of 2020.
  • Interest expense was $13.5 million in the second quarter of 2021, compared to $2.9 million in the second quarter of 2020.

Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference

Retrieved on: 
Wednesday, August 4, 2021

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.

Key Points: 
  • Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will be presenting during a fireside chat at the upcoming virtual Wedbush PacGrow Healthcare Conference on Tuesday, August 10th, 2021 at 8:35am ET.
  • The session entitled HAE There- Development Landscape in Hereditary Angioedema (HAE) will include an overview of the HAE treatment landscape, information about Catabasiss lead program QLS-215, and a Q&A session.
  • At Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families affected by rare and niche diseases.
  • Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.

FDA Approves New BERINERT® (C1 Esterase Inhibitor, Human (Intravenous)) Administration Kit for Increased Patient Convenience

Retrieved on: 
Tuesday, August 3, 2021

"Regardless of being on a preventive therapy or not, being prepared to rapidly treat an HAE attack is of utmost importance.

Key Points: 
  • "Regardless of being on a preventive therapy or not, being prepared to rapidly treat an HAE attack is of utmost importance.
  • BERINERT is a plasma-derived C1 Esterase Inhibitor (Human) indicated for the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) attacks in adult and pediatric patients.
  • CSL Behring has marketed its C1 Esterase Inhibitor concentrate, BERINERT, in Germany for more than 30 years.
  • Serious arterial and venous thromboembolic (TE) events have been reported following administration of recommended doses of C1 Esterase Inhibitor (Human) products to patients with HAE.

BioCryst Appoints Vincent Milano to Board of Directors

Retrieved on: 
Wednesday, July 28, 2021

RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., July 28, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.
  • Prior to joining ViroPharma in 1996, he served as a senior manager at KPMG LLP, an independent registered public accounting firm.
  • Mr. Milano currently serves on the boards of directors of Idera Pharmaceuticals, Aclaris Therapeutics and VenatoRx Pharmaceuticals, and is the chairman of the board for Life Science Cares Philadelphia.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.

KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significantly Slows Progression and Accelerates Resolution of Attacks in Patients with HAE

Retrieved on: 
Monday, July 12, 2021

As KVD900 halted attack progression and resolved attacks more quickly in patients with HAE, while demonstrating a good safety and tolerability profile, it could be a valued choice for physicians and patients in managing HAE.

Key Points: 
  • As KVD900 halted attack progression and resolved attacks more quickly in patients with HAE, while demonstrating a good safety and tolerability profile, it could be a valued choice for physicians and patients in managing HAE.
  • The late-breaking poster, titled A single on-demand treatment with orally administered KVD900 significantly slows progression and accelerates resolution of attacks in patients with hereditary angioedema (HAE): results of a phase 2, placebo-controlled, double-blind cross-over trial, contains the comprehensive data set from the companys Phase 2 clinical trial of KVD900 in HAE patients.
  • KalVista presented four other posters at EAACI related to the HAE clinical landscape and unmet needs, as well as preclinical data from other oral molecules.
  • Patients with nC1-HAE may represent a more sizeable population of patients with HAE in the U.S. than previously suspected.

New Data from the Phase 3 HELP Study™ Open-Label Extension Evaluating Safety and Efficacy of TAKHZYRO® (lanadelumab) for Hereditary Angioedema Patients to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress

Retrieved on: 
Saturday, July 10, 2021

TAKHZYRO, which has a half-life of approximately 14 days, is expected to reach steady state at approximately 70 days.

Key Points: 
  • TAKHZYRO, which has a half-life of approximately 14 days, is expected to reach steady state at approximately 70 days.
  • These analyses further assert the important role TAKHZYRO can play in the lives of people who live with HAE.
  • The HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE) is an evaluation of the long-term efficacy and safety of TAKHZYRO in hereditary angioedema (HAE) patients of at least 12 years of age and older.
  • Rollover patients received a dose of 300 mg TAKHZYRO on Day 0 and then every two weeks after their first attack.

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2022 Results: August 11, 2021

Retrieved on: 
Friday, July 9, 2021

BOSTON, July 9, 2021 /PRNewswire/ --Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2022 financial results at 6:00 am EDT on Wednesday, August 11, 2021.

Key Points: 
  • BOSTON, July 9, 2021 /PRNewswire/ --Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2022 financial results at 6:00 am EDT on Wednesday, August 11, 2021.
  • The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on August 11, 2021.
  • The call can be accessed with the following information:
    U.S. / Canada toll free (877) 848-8880; International (716) 335-9512
    Conference ID required for access: 1674067
    A live webcast of the call can be accessed on Haemonetics' investor relations website.
  • Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services.

KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop

Retrieved on: 
Saturday, June 5, 2021

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the oral presentation of clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) at the 12th C1-Inhibitor Deficiency & Angioedema Workshop.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced the oral presentation of clinical data supporting KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) at the 12th C1-Inhibitor Deficiency & Angioedema Workshop.
  • KVD900 significantly accelerated improvement in attack severity as assessed using a composite Visual Analog Scale (VAS).
  • KalVista has developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).
  • KalVista is developing KVD900 as an oral on-demand therapy for acute HAE attacks, which completed a Phase 2 efficacy trial in February 2021, demonstrating statistical and clinical significance across all endpoints.